Quarterly report pursuant to Section 13 or 15(d)

Revenues

v3.20.2
Revenues
6 Months Ended
Jun. 30, 2020
Revenues  
Revenues

7.

Revenues

Revenues disaggregated by category were as follows (in thousands):

Three Months Ended 

Six Months Ended 

June 30, 

June 30, 

2020

    

2019

2020

    

2019

Product sales:

Gross product sales

$

18,353

$

12,481

$

33,724

$

22,397

Discounts and allowances

(3,379)

(2,308)

(6,070)

(4,170)

Product sales, net

$

14,974

$

10,173

$

27,654

$

18,227

Revenues from collaborations:

License revenues

39,858

4,499

Research and development services and others

1,047

234

4,270

305

Total revenues from collaborations

1,047

234

44,128

4,804

Total revenues

$

16,021

$

10,407

$

71,782

$

23,031

The following table summarizes revenues from each of our customers who individually accounted for 10% or more of our total revenues (as a percentage of total revenues):

Three Months Ended 

Six Months Ended 

June 30, 

June 30, 

2020

    

2019

2020

    

2019

ASD Healthcare and Oncology Supply

47%

48%

20%

40%

McKesson Specialty Care Distribution Corporation

41%

40%

16%

31%

Cardinal Healthcare

5%

10%

2%

Grifols

7%

61%

20%

We commenced commercial sale of TAVALISSE in the U.S. in May 2018 after FDA approval in April 2018. Our MAA for fostamatinib for the treatment of chronic ITP in adult patients who are refractory to other treatments was approved by the EC in January 2020.

In addition to the distribution agreements with our customers and SDs, we also enter into arrangements with specialty pharmacy providers, in-office dispensing providers, group purchasing organizations, and government entities that provide for government-mandated and/or privately-negotiated rebates, chargebacks and discounts with respect to the purchase of our products which reduced our gross product sales. Also refer to Revenue Recognition policy discussion in “Note 3” above.

The following table summarizes activity in each of the product revenue allowance and reserve categories for the six months ended June 30, 2020 and 2019 (in thousands):

Chargebacks,

Government

Discounts and

and Other

Fees

Rebates

Returns

Total

Balance at January 1, 2020

    

$

1,293

 

$

1,801

$

238

$

3,332

Provision related to current period sales

3,381

1,747

128

5,256

Adjustment related to prior period sales

(75)

(257)

332

Credit or payments made during the period

(2,615)

(1,593)

(58)

(4,266)

Balance at June 30, 2020

 

$

1,984

$

1,698

$

640

$

4,322

Chargebacks,

Government

Discounts and

and Other

Fees

Rebates

Returns

Total

Balance at January 1, 2019

    

$

622

 

$

843

$

170

$

1,635

Provision related to current period sales

2,055

1,559

99

3,713

Credit or payments made during the period

(1,682)

(930)

(2,612)

Balance at June 30, 2019

 

$

995

$

1,472

$

269

$

2,736

The discounts and allowances from gross product sales for the six months ended June 30, 2020 of $6.1 million in the first table above includes the provision for current period sales of $5.3 million which formed part of Other Accrued Liabilities in the balance sheet of which $4.3 million remained outstanding as of June 30, 2020. Of the $6.1 million discounts and allowances from gross sales, $796,000 is recorded as reduction in accounts receivable and prepaid and other current assets in the balance sheet.